Brainstorm Cell Therapeutics Inc. (BCLI)
- Previous Close
0.5450 - Open
0.5489 - Bid 0.4940 x 300
- Ask 0.5679 x 300
- Day's Range
0.5210 - 0.5550 - 52 Week Range
0.1300 - 3.3400 - Volume
266,966 - Avg. Volume
1,010,345 - Market Cap (intraday)
36.358M - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4000 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.50
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
www.brainstorm-cell.comRecent News: BCLI
Performance Overview: BCLI
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BCLI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BCLI
Valuation Measures
Market Cap
36.36M
Enterprise Value
36.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.72
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-211.70%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.19M
Diluted EPS (ttm)
-0.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
1.3M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-12.49M